{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:33:54Z","timestamp":1773477234453,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":4286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Gr\u00fcnenthal GmbH"},{"name":"Zaicom MMC Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.fertnstert.2009.06.057","type":"journal-article","created":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T05:37:05Z","timestamp":1251265025000},"page":"1195-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24\/4-day intake regimen over three cycles"],"prefix":"10.1016","volume":"94","author":[{"given":"J\u00fcrgen","family":"Spona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"H\u00f6schen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Feichtinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2009.06.057_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/bmj.2.5703.231","article-title":"A statement by the committee on safety of drugs","volume":"2","author":"Combined oral contraceptives","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib2","first-page":"1058","article-title":"Recommendations on oral contraception","volume":"38","author":"Bettendorf","year":"1997","journal-title":"Der Frauenarzt"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.2.5704.293","article-title":"R.C.O.G. statement on oral contraceptives","volume":"2","author":"Jeffcoate","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","article-title":"Ultrasound evaluation of ovarian activity under oral contraceptives","volume":"47","author":"Hoogland","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13625180701619247","article-title":"Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara\u00ae, over three medication cycles","volume":"13","author":"Spona","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0010-7824(97)00123-6","article-title":"Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest","volume":"56","author":"Spona","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0010-7824(96)00183-7","article-title":"Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0010-7824(01)00235-9","article-title":"Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2008.02.019","article-title":"Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24\/4 regimen","volume":"78","author":"Klipping","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dot.2008.44.2.1191057","article-title":"Drospirenone\/ethinyl estradiol","volume":"44","author":"Rapkin","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2009.02.016","article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","volume":"80","author":"Plewig","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13625189909040809","article-title":"A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel","volume":"4","author":"Winkler","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2007.12.007","volume":"77","author":"Zahradnik","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.contraception.2010.01.011","article-title":"Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24\/4-day regimen","volume":"81","author":"Brucker","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib20","first-page":"295","article-title":"Diagnosis and treatment of the cervical factor of infertility","volume":"5","author":"Insler","year":"1981","journal-title":"Reproduccion"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/j.1879-3479.1972.tb00857.x","article-title":"The cervical score","volume":"10","author":"Insler","year":"1972","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0010-7824(01)00232-3","article-title":"Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(01)00258-X","article-title":"Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene","volume":"64","author":"Ludicke","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1701-2163(16)30692-2","article-title":"Ovarian follicular development during the use of oral contraception: a review","volume":"26","author":"Baerwald","year":"2004","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF01986524","article-title":"A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation","volume":"10","author":"Fitzgerald","year":"1994","journal-title":"Adv Contracept"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0015-0282(16)60967-6","article-title":"Ovarian follicles during oral contraceptive cycles: their potential for ovulation","volume":"52","author":"Killick","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0010-7824(79)90053-2","article-title":"Pituitary and ovarian function in women receiving hormonal contraception","volume":"20","author":"Cohen","year":"1979","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib29","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/humrep\/deh493","article-title":"Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study","volume":"19","author":"Duijkers","year":"2004","journal-title":"Hum Reprod"},{"issue":"Suppl 1","key":"10.1016\/j.fertnstert.2009.06.057_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13625180500434962","article-title":"Belara\u2014proven benefits in daily practice","volume":"10","author":"Bitzer","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003495-200464070-00005","article-title":"Ethinylestradiol\/chlormadinone acetate","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.fertnstert.2009.06.057_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13625180500434897","article-title":"Belara\u2014a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea","volume":"10","author":"Zahradnik","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.fertnstert.2009.06.057_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0010-7824(01)00221-9","article-title":"Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol\/100 microg levonorgestrel and 20 microg ethinylestradiol\/500 microg norethisterone","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028209014319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028209014319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:43:13Z","timestamp":1758008593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028209014319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0015028209014319"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2009.06.057","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24\/4-day intake regimen over three cycles","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2009.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}